Microbial Robotics briefing
?
1 like?283 views
This document discusses Microbial Robotics' open synthetic biology model and business plan. The company aims to rapidly prototype synthetic biology-based bacteria and viruses for industry experts through an open model. By shipping consumables, platforms, and knowledge across borders instead of genetically modified organisms, the company solves issues around international shipping restrictions. The company also focuses on achieving rapid return on investment through its Open Therapeutics subsidiary and exit strategy within 5 years of starting projects. Projections estimate strong revenue, margin, and EBITDA growth through 2019 as subsidiaries are acquired by larger companies.
![WHY OPEN SYNTHETIC BIOLOGY MODEL?
[11] United States Patent and Trademark Of?ce, Patent Pools:A Solution to the Problem of Access in Biotechnology Patents? (Dec 5, 2000)
available at http://www.uspto.gov/web/of?ces/pac/dapp/opla/patentpool.pdf .The USPTO noted two of the most pro?table in the biotechnology
area are those of Cohen and Boyer, which are owned by Stanford University. Stanford minimized licensing fees and extended non-exclusive
licenses.This discouraged would-be infringers since the cost of obtaining a license is low. Instead of encourage infringement and patent trolling,
the ease of non-exclusive licenses meant broad distribution and spurred further innovation. See also National Research Council, Intellectual
Property Rights and Research Tools in Molecular Biology (1996), available at http://www.nap.edu/readingroom/books/property/5.html. ?
¡°With respect to biologics commercialization, the U.S. Patent andTrademark Of?ce
(USPTO) speci?cally noted the open (patent-pool) approach:
¡®No single company or organization, however, has the resources to develop any
signi?cant fraction of the genetic information present in an organism. If proprietary
information is not freely available or licensed in an affordable manner, researchers
will be precluded from using these protected nucleic acids to develop new
therapeutics and diagnostics. It would be, however, shortsighted of a patent holder
to demand such a prohibitively expensive licensing agreement that would preclude
anyone else from utilizing a patented invention. . . . By minimizing licensing fees and
extending non-exclusive licenses, potential infringers were inclined to obtain
licenses and the technology was therefore broadly distributed. . . .¡¯[11]¡±](https://image.slidesharecdn.com/microbialroboticsbriefingdeck-150519160453-lva1-app6891/85/Microbial-Robotics-briefing-3-320.jpg)
Microbial Robotics briefing
- 1. THIS ?IS ?NOT ?AN ?OFFERING ?TO ?BUY ?OR ?SELL ?SECURITIES ? Safe ?Harbor ?for ?Forward-?©\Looking ?Statements Except for the statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Microbial Robotics LLC (the ¡°Company¡±) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to fund operations, the ability to forge partnerships required for deployment, changes in consumer and corporate buying habits, energy development, production, and distribution, the rapid pace of change in the technology industry and other factors over which the Companies have little or no control. The Companies assume no obligation to publicly update or revise any forward-looking statements. A full Risk Disclosure is available within the business plan. Your advancement beyond this page or slide into this document indicates you read and understand this disclosure. The remaining aspects of this document are confidential. The contents should not be disclosed beyond you without the expressed written consent of the Company. 1
- 2. WITH SMALL ORGANISMS With an Open model, rapidly prototyping synthetic biology-based bacteria and viruses for chemical, therapeutic, and water industry experts. SOLVING BIG PROBLEMS JASON E. BARKELOO, CEO
- 3. WHY OPEN SYNTHETIC BIOLOGY MODEL? [11] United States Patent and Trademark Of?ce, Patent Pools:A Solution to the Problem of Access in Biotechnology Patents? (Dec 5, 2000) available at http://www.uspto.gov/web/of?ces/pac/dapp/opla/patentpool.pdf .The USPTO noted two of the most pro?table in the biotechnology area are those of Cohen and Boyer, which are owned by Stanford University. Stanford minimized licensing fees and extended non-exclusive licenses.This discouraged would-be infringers since the cost of obtaining a license is low. Instead of encourage infringement and patent trolling, the ease of non-exclusive licenses meant broad distribution and spurred further innovation. See also National Research Council, Intellectual Property Rights and Research Tools in Molecular Biology (1996), available at http://www.nap.edu/readingroom/books/property/5.html. ? ¡°With respect to biologics commercialization, the U.S. Patent andTrademark Of?ce (USPTO) speci?cally noted the open (patent-pool) approach: ¡®No single company or organization, however, has the resources to develop any signi?cant fraction of the genetic information present in an organism. If proprietary information is not freely available or licensed in an affordable manner, researchers will be precluded from using these protected nucleic acids to develop new therapeutics and diagnostics. It would be, however, shortsighted of a patent holder to demand such a prohibitively expensive licensing agreement that would preclude anyone else from utilizing a patented invention. . . . By minimizing licensing fees and extending non-exclusive licenses, potential infringers were inclined to obtain licenses and the technology was therefore broadly distributed. . . .¡¯[11]¡±
- 5. YEARS Pablo Pomposiello? PhD Bacterial Physiology Consultant Timothy P. Cripe MD, PhD Oncolytics Consultant Ravi N. Samy MD, FACS Chief Medical Of?cer Jason E. Barkeloo MA Founder & CEO Shengchang Su PhD Director MicrobialBots and GeRM Engineering? Li Guo PhD Director Cellular Engineering Jay Springer JD Director Regulatory ? and Legal Affairs Jin Kong JD Director GlobalSynBio & Open Therapeutics EXPERIENCE 100+ K. Krishnamoorthy MD Chief Medical Of?cer India
- 6. ¡°Imagine a cancer cure without the destructive side effects of chemotherapy. This leader in pediatric research is doing just that.¡±
- 9. WHY NOW? $18B $9B 2008 2012 2016 Research and Markets, May 2014 2013 2020 CAGR $3 BILLION $40 BILLION 44%
- 10. Can¡¯t ship GMOs Across borders Can¡¯t Ship GMOs across borders 1ST BOTTLENECK
- 11. Ship GeRM, consumables, and knowledge across borders, not GMOs. 1ST BOTTLENECK SOLVED
- 13. 2ND BOTTLENECK SOLVED Focus on Rapid ROI t 12 months 5 years Clinical trials Productization expert MARKETS Rapid prototyping Open Therapeutics
- 14. Exit Zone 5 years aquaculture denitri?cation (DeNitro Water) gold precipitate (Aureus Water) NON-OPERATING SUBSIDIARY PIPELINE aquaculture probiotic (Fish Probiotic) cholesteatoma lytic (Auricle Solutions) breast cancer (Pectus Lytics) neuroblastoma (Neurolytics) cancer screen (LightOwl Biomarkers) cholesteatoma lytic (AureMed) 12 months
- 15. SUBSIDIARY ACQUIRERSalso competitors water chemicals therapeutics WASTE WATER-TO-VALUE FUELS & BUILDING BLOCKS ANTIBIOTICS & ONCOLYTICS
- 16. PROJECTIONS Very low cost to scale Break-even 2015 2016 2017 2018 2019 Net Income $(433,884) $4,456,716 $11,129,052 $18,130,972 $32,300,094 Net Margin -12% 32% 44% 49% 54% EBITDA $(619,400) $6,540,600 $16,174,200 $26,478,400 $46,841,200 EBITDA (Percent) -16% 48% 64% 71% 79%
- 20. TEAM PRODUCTS MARKETS EXIT ROIs JASON E. BARKELOO, CEO jason@MicrobialRobotics.com +1.513.225.8765